Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Glaucoma 2.0: Neuroprotection, Neuroregeneration, Neuroenhancement OPHTHALMOLOGY Chang, E. E., Goldberg, J. L. 2012; 119 (5): 979-986

Abstract

Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve. Clinically, our only method of slowing glaucomatous loss of vision is to reduce intraocular pressure (IOP), but lowering IOP is only partially effective and does not address the underlying susceptibility of RGCs to degeneration. We review the recent steps forward in our understanding of the pathophysiology of glaucoma and discuss how this understanding has given us a next generation of therapeutic targets by which to maintain RGC survival, protect or rebuild RGC connections in the retina and brain, and enhance RGC function.

View details for DOI 10.1016/j.ophtha.2011.11.003

View details for Web of Science ID 000303399800014

View details for PubMedID 22349567

View details for PubMedCentralID PMC3343191